Exciting developments are brewing at Sonoma Biotherapeutics, the clinical-stage biotech company focused on engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases. Today, they’ve announced two remarkable additions to their leadership team.
First, meet Dr. Joseph R. Arron, the new Chief Scientific Officer (CSO). Dr. Arron is no stranger to groundbreaking research, with extensive experience in drug discovery and biomarker development. He’s already been a vital member of the company’s Scientific Advisory Board.
Dr. Arron’s previous role as Chief Scientific Officer at 23andMe, a genetics-driven healthcare company, showcased his talents in target discovery and preclinical development for genetic-related diseases. With a Ph.D. from The Rockefeller University and an M.D. from Weill Medical College of Cornell University, he’s a true powerhouse in the field.
Then, there’s Dr. Mark D. Eisner, the freshly appointed Chief Medical Officer (CMO). Dr. Eisner brings a wealth of experience in clinical development, spanning various therapeutic areas like immunology, fibrosis, ophthalmology, and infectious diseases. He’s previously held top positions at FibroGen, overseeing the clinical development of their pipeline.
Dr. Eisner’s journey in the biopharmaceutical world began at Genentech, where he played key roles in clinical and medical leadership. He earned his M.D. from the University of Pennsylvania School of Medicine, an MPH from UC Berkeley, and holds an undergraduate degree in human biology from Stanford University.
The team at Sonoma Bio is enthusiastic about this dynamic duo joining their ranks, and for good reason. With their combined expertise, they’re set to propel the development of next-generation Treg cell therapies and usher in a new era in autoimmune disease treatment. The company’s mission to revolutionize the chronic treatment landscape for patients is now in even more capable hands.
About Sonoma Biotherapeutics
Picture a clinical-stage biotech company on the cusp of transforming the way we treat autoimmune and inflammatory diseases. That’s Sonoma Biotherapeutics. Driven by a team of pioneers in Treg biology and cell therapy, they’re not just pushing boundaries; they’re redefining them.
At the heart of their mission is the development of engineered regulatory T cell (Treg) therapies. These cutting-edge treatments aim to restore balance to the immune system, offering new hope to those battling serious diseases.
With proprietary platform technologies and innovative approaches, Sonoma Biotherapeutics is paving the way for a generation of targeted and long-lasting Treg cell therapies. They’re based in the dynamic hubs of South San Francisco and Seattle, where groundbreaking science meets a relentless commitment to improving lives.